MetaVia shares plunge on FY2025 earnings miss as cash runway concerns mount
Clinical-stage biotech reported -$7.35 EPS versus -$0.25 estimate, highlighting path to profitability challenges
MetaVia Inc. shares extended their precipitous decline on Wednesday after the clinical-stage biotechnology company reported full fiscal year 2025 results that dramatically missed analyst expectations, raising fresh concerns about the company's path to profitability and cash runway sustainability.
The Cambridge, Massachusetts-based company reported earnings per share of negative $7.35, far short of the consensus estimate for a loss of $0.25 per share—a catastrophic 2,840% earnings miss that underscores the challenges facing the drug developer. While the net loss narrowed significantly from the $39.13 per share loss recorded in fiscal year 2024, the magnitude of the miss caught investors off guard.
The company's research and development spending fell sharply to $6.8 million from $21.6 million in the prior year, reflecting a strategic shift toward conserving capital. MetaVia ended fiscal 2025 with [cash and cash equivalents of $10.3 million], bolstered by $9.3 million in proceeds from a January public offering. However, the combined $19.6 million in cash is expected to fund operations only into the fourth quarter of 2026, creating what analysts see as a significant dilution risk for shareholders.
MetaVia, which changed its name from NeuroBo Pharmaceuticals in November 2024, is developing therapies targeting cardiometabolic diseases. Its two primary drug candidates include [DA-1726], a novel oxyntomodulin analogue that functions as a dual agonist of GLP-1 and glucagon receptors for obesity and MASH (Metabolic Dysfunction-Associated Steatohepatitis), and [vanoglipel (DA-1241)], a GPR119 agonist also targeting MASH.
The company recently released [positive data from an 8-week Phase 1 cohort of DA-1726], demonstrating 9.1% weight loss and statistically significant improvements in glucose control and liver stiffness without titration. Those results helped secure Institutional Review Board approval for a Phase 1 Part 3 trial evaluating higher doses of up to 64 mg, with initiation expected in April 2026 and data anticipated in the fourth quarter of 2026.
Despite the promising clinical progress, the stock has been in a sustained downtrend, [trading at $1.30], well below both its 50-day moving average of $2.47 and 200-day moving average of $7.13. Over the past 12 months, [the shares have declined more than 90%], falling from a 52-week high above $20 to current levels. The market capitalization has dwindled to approximately $4.8 million.
The disconnect between MetaVia's clinical pipeline progress and its severe stock performance reflects broader challenges facing clinical-stage biotechnology companies in the current funding environment. With no revenue and a cash runway that expires within 18 months, the company faces pressure to either advance its programs to value-creating milestones or return to capital markets for additional funding—likely at terms that would further dilute existing shareholders.
MetaVia faces stiff competition in the GLP-1 obesity market, which is dominated by pharmaceutical giants including Novo Nordisk and Eli Lilly. Those companies have achieved multibillion-dollar valuations with their weight-loss drugs, raising the bar for smaller competitors seeking to demonstrate differentiation and clinical superiority.
Analysts maintain a bullish outlook on the stock, with [a consensus target price of $35.67] based on ratings from three analysts—one strong buy and two buy recommendations. However, achieving those targets would require multiple successful clinical milestones and a funding strategy that minimizes dilution, a path that appears increasingly challenging given the company's current financial trajectory.
The company's next major catalyst will be the Phase 1 Part 3 trial data for DA-1726, expected in the fourth quarter of 2026. That timeline coincides with its cash runway expiration, creating a narrow window for MetaVia to demonstrate value to investors before seeking additional capital.